STAT Plus: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition
MorphoSys is dealing with an emerging safety issue related to pelabresib, the experimental treatment for myelofibrosis, STAT has learned.